602 related articles for article (PubMed ID: 35961255)
21. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
22. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
23. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
24. The Safety Profile of Common COVID-19 Vaccines in Patients With Multiple Sclerosis.
Aladdin YS; Alqarni DA; Alamoudi SW; Alharbi AA; Fudhah WA; Alghamdi G; Attar A
Cureus; 2024 Feb; 16(2):e54852. PubMed ID: 38533153
[TBL] [Abstract][Full Text] [Related]
25. Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies.
Drulovic J; Ivanovic J; Martinovic V; Tamas O; Veselinovic N; Cujic D; Gnjatovic M; Mesaros S; Pekmezovic T
Mult Scler Relat Disord; 2021 Sep; 54():103150. PubMed ID: 34298478
[TBL] [Abstract][Full Text] [Related]
26. Vaccine hesitancy among people with multiple sclerosis.
Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
[TBL] [Abstract][Full Text] [Related]
27. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
28. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
Kerr S; Joy M; Torabi F; Bedston S; Akbari A; Agrawal U; Beggs J; Bradley D; Chuter A; Docherty AB; Ford D; Hobbs R; Katikireddi SV; Lowthian E; de Lusignan S; Lyons R; Marple J; McCowan C; McGagh D; McMenamin J; Moore E; Murray JK; Owen RK; Pan J; Ritchie L; Shah SA; Shi T; Stock S; Tsang RSM; Vasileiou E; Woolhouse M; Simpson CR; Robertson C; Sheikh A
PLoS Med; 2022 Feb; 19(2):e1003927. PubMed ID: 35192598
[TBL] [Abstract][Full Text] [Related]
29. Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis.
Etemadifar M; Abhari AP; Nouri H; Sigari AA; Piran Daliyeh SM; Maracy MR; Salari M; Maleki S; Sedaghat N
Hum Vaccin Immunother; 2022 Dec; 18(1):2041945. PubMed ID: 35201963
[TBL] [Abstract][Full Text] [Related]
30. Adverse Events Following Immunization With mRNA and Viral Vector Vaccines in Individuals With Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection From the Canadian National Vaccine Safety Network.
Bettinger JA; Irvine MA; Shulha HP; Valiquette L; Muller MP; Vanderkooi OG; Kellner JD; Top KA; Sadarangani M; McGeer A; Isenor JE; Marty K; Soe P; De Serres G;
Clin Infect Dis; 2023 Mar; 76(6):1088-1102. PubMed ID: 36310514
[TBL] [Abstract][Full Text] [Related]
31. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
[TBL] [Abstract][Full Text] [Related]
32. COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose.
Dreyer-Alster S; Menascu S; Mandel M; Shirbint E; Magalashvili D; Dolev M; Flechter S; Givon U; Guber D; Stern Y; Miron S; Polliack M; Falb R; Sonis P; Gurevich M; Achiron A
J Neurol Sci; 2022 Mar; 434():120155. PubMed ID: 35091386
[TBL] [Abstract][Full Text] [Related]
33. Safety of Sinopharm vaccine for people with Multiple Sclerosis: Study of adverse reactions and disease activity.
Kavosh A; Ashtari F; Naghavi S; Adibi I; Shaygannejad V; Karimi Z; Arabi S; Rahimi M; Mazaheri S
Mult Scler Relat Disord; 2022 May; 61():103708. PubMed ID: 35349883
[TBL] [Abstract][Full Text] [Related]
34. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
35. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies.
Ozakbas S; Baba C; Dogan Y; Cevik S; Ozcelik S; Kaya E
Mult Scler Relat Disord; 2022 Feb; 58():103486. PubMed ID: 35032878
[TBL] [Abstract][Full Text] [Related]
36. Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience.
Bertozzi A; Mariottini A; Marchi L; Cristinzi MD; Nistri R; Damato V; Mechi C; Barilaro A; Massacesi L; Repice AM
Mult Scler Relat Disord; 2023 Apr; 72():104582. PubMed ID: 36889098
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
[TBL] [Abstract][Full Text] [Related]
38. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac
Chatsiricharoenkul S; Niyomnaitham S; Posen HJ; Toh ZQ; Licciardi PV; Wongprompitak P; Duangchinda T; Pakchotanon P; Chantima W; Chokephaibulkit K
Front Immunol; 2022; 13():1010835. PubMed ID: 36268028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]